Abstract
Rosiglitazone is the second of the marketed thiazolidinediones to fall from grace, and its demise bears an uncanny resemblance to the earlier downfall of troglitazone. Both narratives demonstrate the inadequacy of a regulatory system that is mandated to place a higher value on commercial secrecy than on patient safety.
MeSH terms
-
Chromans / adverse effects
-
Chromans / therapeutic use
-
Diabetes Mellitus / drug therapy
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use*
-
Rosiglitazone
-
Thiazolidinediones / adverse effects
-
Thiazolidinediones / therapeutic use*
-
Troglitazone
Substances
-
Chromans
-
Hypoglycemic Agents
-
Thiazolidinediones
-
Rosiglitazone
-
Troglitazone